LONDON, July 06, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the American Medical Association has released the language of its new Current Procedural Terminology (CPT®) III code for Continuous In-Person Monitoring and Intervention During…

Source

Previous articlePT421 – The Impact of the Therapeutic Alliance on the Psychedelic Experience
Next articleRevive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19